The role of co-morbidities on total hip replacement outcome
Objective: Co-morbidities may influence the clinical response to total hip replacement (THR); however, limited information is available for specific or multiple co-morbidities. We aimed to analyse this association in a large population-based setting. Methods: Patients of the Dresden Hip Surgery Regi...
| मुख्य लेखकों: | , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| भाषा: | English |
| प्रकाशित: |
2012
|
| _version_ | 1826281137374232576 |
|---|---|
| author | Schäfer, T Al Daboubi, F Dieppe, P Judge, A Kirschner, S Krummenauer, F Günther, K |
| author_facet | Schäfer, T Al Daboubi, F Dieppe, P Judge, A Kirschner, S Krummenauer, F Günther, K |
| author_sort | Schäfer, T |
| collection | OXFORD |
| description | Objective: Co-morbidities may influence the clinical response to total hip replacement (THR); however, limited information is available for specific or multiple co-morbidities. We aimed to analyse this association in a large population-based setting. Methods: Patients of the Dresden Hip Surgery Registry were recruited. Pre- and postoperative (6 months) functional status was assessed by the global WOMAC score (0-100 pts). Clinical non-response was defined as a gain of <20 points within 6 months in the global WOMAC score and analysed with respect to co-morbidities. Multiple logistic regression modelling was applied to adjust for age, sex, BMI, school education, and preoperative functional status. Results: A total of 1,002 patients (mean age 61 years, STD 13; 55 % women) were studied. The average preoperative WOMAC score was 45. 7 increasing to 84. 4 after surgery. One hundred four patients (12. 9 %) were classified as clinical non-responders. Two thirds of the patients (66. 2 %) reported at least one co-morbidity. After controlling for confounders, the presence of coagulopathy, electrolyte disorder, and tumour was associated with a significantly elevated risk of clinical non-response (OR 7. 58, CI 2. 46-23. 33; OR 5. 92, CI 1. 68-20. 85; OR 5. 55, CI 1. 38-22. 30). The presence of three (OR 3. 26, CI 1. 47-7. 21) or more (OR 2. 86, CI 1. 03-7. 89) co-morbidities increased the risk of clinical non-response significantly, whereas a single co-morbidity did not (OR 0. 75, CI 0. 39-1. 44). Conclusion: The results of this study may help to identify subgroups of patients with specific or numerous co-morbidities who need special care and attention as they have an increased risk of clinical non-response after THR. © 2012 EFORT. |
| first_indexed | 2024-03-07T00:24:16Z |
| format | Journal article |
| id | oxford-uuid:7d963e40-ca5d-4230-823c-189cb55289c2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:24:16Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:7d963e40-ca5d-4230-823c-189cb55289c22022-03-26T21:04:42ZThe role of co-morbidities on total hip replacement outcomeJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7d963e40-ca5d-4230-823c-189cb55289c2EnglishSymplectic Elements at Oxford2012Schäfer, TAl Daboubi, FDieppe, PJudge, AKirschner, SKrummenauer, FGünther, KObjective: Co-morbidities may influence the clinical response to total hip replacement (THR); however, limited information is available for specific or multiple co-morbidities. We aimed to analyse this association in a large population-based setting. Methods: Patients of the Dresden Hip Surgery Registry were recruited. Pre- and postoperative (6 months) functional status was assessed by the global WOMAC score (0-100 pts). Clinical non-response was defined as a gain of <20 points within 6 months in the global WOMAC score and analysed with respect to co-morbidities. Multiple logistic regression modelling was applied to adjust for age, sex, BMI, school education, and preoperative functional status. Results: A total of 1,002 patients (mean age 61 years, STD 13; 55 % women) were studied. The average preoperative WOMAC score was 45. 7 increasing to 84. 4 after surgery. One hundred four patients (12. 9 %) were classified as clinical non-responders. Two thirds of the patients (66. 2 %) reported at least one co-morbidity. After controlling for confounders, the presence of coagulopathy, electrolyte disorder, and tumour was associated with a significantly elevated risk of clinical non-response (OR 7. 58, CI 2. 46-23. 33; OR 5. 92, CI 1. 68-20. 85; OR 5. 55, CI 1. 38-22. 30). The presence of three (OR 3. 26, CI 1. 47-7. 21) or more (OR 2. 86, CI 1. 03-7. 89) co-morbidities increased the risk of clinical non-response significantly, whereas a single co-morbidity did not (OR 0. 75, CI 0. 39-1. 44). Conclusion: The results of this study may help to identify subgroups of patients with specific or numerous co-morbidities who need special care and attention as they have an increased risk of clinical non-response after THR. © 2012 EFORT. |
| spellingShingle | Schäfer, T Al Daboubi, F Dieppe, P Judge, A Kirschner, S Krummenauer, F Günther, K The role of co-morbidities on total hip replacement outcome |
| title | The role of co-morbidities on total hip replacement outcome |
| title_full | The role of co-morbidities on total hip replacement outcome |
| title_fullStr | The role of co-morbidities on total hip replacement outcome |
| title_full_unstemmed | The role of co-morbidities on total hip replacement outcome |
| title_short | The role of co-morbidities on total hip replacement outcome |
| title_sort | role of co morbidities on total hip replacement outcome |
| work_keys_str_mv | AT schafert theroleofcomorbiditiesontotalhipreplacementoutcome AT aldaboubif theroleofcomorbiditiesontotalhipreplacementoutcome AT dieppep theroleofcomorbiditiesontotalhipreplacementoutcome AT judgea theroleofcomorbiditiesontotalhipreplacementoutcome AT kirschners theroleofcomorbiditiesontotalhipreplacementoutcome AT krummenauerf theroleofcomorbiditiesontotalhipreplacementoutcome AT guntherk theroleofcomorbiditiesontotalhipreplacementoutcome AT schafert roleofcomorbiditiesontotalhipreplacementoutcome AT aldaboubif roleofcomorbiditiesontotalhipreplacementoutcome AT dieppep roleofcomorbiditiesontotalhipreplacementoutcome AT judgea roleofcomorbiditiesontotalhipreplacementoutcome AT kirschners roleofcomorbiditiesontotalhipreplacementoutcome AT krummenauerf roleofcomorbiditiesontotalhipreplacementoutcome AT guntherk roleofcomorbiditiesontotalhipreplacementoutcome |